What is Leerink Partnrs’ Forecast for TNYA Q1 Earnings?

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) – Leerink Partnrs issued their Q1 2025 earnings per share (EPS) estimates for shares of Tenaya Therapeutics in a report issued on Tuesday, April 1st. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($0.16) per share for the quarter. The consensus estimate for Tenaya Therapeutics’ current full-year earnings is ($1.35) per share. Leerink Partnrs also issued estimates for Tenaya Therapeutics’ Q2 2025 earnings at ($0.17) EPS, Q3 2025 earnings at ($0.17) EPS and FY2026 earnings at ($0.69) EPS.

Tenaya Therapeutics (NASDAQ:TNYA) last issued its quarterly earnings results on Monday, March 17th. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.04.

Several other equities analysts have also issued reports on the company. Canaccord Genuity Group dropped their price target on Tenaya Therapeutics from $18.00 to $6.00 and set a “buy” rating on the stock in a research note on Thursday, March 13th. Morgan Stanley dropped their target price on shares of Tenaya Therapeutics from $15.00 to $5.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 12th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Tenaya Therapeutics in a report on Monday. Finally, Chardan Capital decreased their price target on shares of Tenaya Therapeutics from $18.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, March 12th. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, Tenaya Therapeutics presently has a consensus rating of “Buy” and an average target price of $6.25.

Tenaya Therapeutics Price Performance

Shares of Tenaya Therapeutics stock opened at $0.57 on Wednesday. The stock’s 50-day moving average is $0.86 and its 200 day moving average is $1.65. Tenaya Therapeutics has a one year low of $0.39 and a one year high of $5.10. The firm has a market cap of $49.56 million, a price-to-earnings ratio of -0.39 and a beta of 2.83.

Insider Activity at Tenaya Therapeutics

In other news, major shareholder Group Gp Lp Column III bought 35,714,284 shares of the company’s stock in a transaction on Wednesday, March 5th. The shares were purchased at an average price of $0.70 per share, with a total value of $24,999,998.80. Following the transaction, the insider now directly owns 49,313,559 shares in the company, valued at $34,519,491.30. This represents a 262.62 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 19,621 shares of company stock valued at $10,595 over the last 90 days. Insiders own 32.76% of the company’s stock.

Institutional Trading of Tenaya Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. increased its position in shares of Tenaya Therapeutics by 20,670.3% during the 4th quarter. JPMorgan Chase & Co. now owns 5,155,596 shares of the company’s stock valued at $7,373,000 after purchasing an additional 5,130,774 shares during the last quarter. Trustees of Columbia University in the City of New York purchased a new position in Tenaya Therapeutics in the fourth quarter valued at about $417,000. Jacobs Levy Equity Management Inc. grew its position in shares of Tenaya Therapeutics by 204.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 337,265 shares of the company’s stock valued at $651,000 after acquiring an additional 226,466 shares during the period. Virtu Financial LLC purchased a new stake in shares of Tenaya Therapeutics during the 4th quarter worth approximately $150,000. Finally, Deutsche Bank AG increased its stake in shares of Tenaya Therapeutics by 304.1% during the 4th quarter. Deutsche Bank AG now owns 129,319 shares of the company’s stock worth $185,000 after purchasing an additional 97,318 shares during the last quarter. 90.54% of the stock is owned by hedge funds and other institutional investors.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.